Syntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedtI
the Illinois Department of Commerce and Economic Opportunity
Activity from announced rounds
Activity in this selectionOct 5, 2026 · Jan 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $14.4M 1 disclosed · full round size, not this investor’s share